Physician profile
Tarek Ammar
NPI 1649478314
$13,505.15
in general payments reported to CMS, 2019-2025
37 companies · $1,832 in 2025
The $1,832 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,821 · 2020: $2,561 · 2021: $3,629 · 2022: $1,083 · 2023: $1,038 · 2024: $1,543 · 2025: $1,832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,558 · Travel and Lodging: $854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,558.18 |
| Travel and Lodging | $853.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $2,829.44 | 2021-2022 | |
| Abbvie INC. | $2,554.68 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Boston Scientific Corporation | $1,834.93 | 2019-2025 | Orise, Overstitch Nxt Endoscopic Suturing System, Spaceoar Vue System - 10ml |
| Qol Medical, LLC | $1,598.95 | 2019-2023 | Sucraid |
| Endogastric Solutions, INC | $709.02 | 2019-2020 | |
| Olympus Corporation of The Americas | $607.62 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $490.51 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Gilead Sciences, INC. | $456.28 | 2019-2024 | |
| Janssen Biotech, INC. | $367.18 | 2021-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $330.31 | 2019-2025 | Entyvio, Eohilia |
| Olympus America INC. | $316.96 | 2019 | |
| Ethicon US, LLC | $162.05 | 2019 | |
| Braintree Laboratories, INC. | $128.73 | 2019-2024 | Sutab, Suflave |
| Cook Medical LLC | $118.61 | 2021 | |
| Ironwood Pharmaceuticals, INC | $103.09 | 2021-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medivators INC. | $85.86 | 2019 | |
| Merck Sharp & Dohme LLC | $78.99 | 2021-2024 | Dificid |
| Alfasigma USA, INC. | $74.93 | 2020-2021 | |
| Pfizer INC. | $70.41 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $67.37 | 2023-2025 | Dupixent |
| Shire North American Group INC | $62.27 | 2019 | |
| Phathom Pharmaceuticals, INC. | $60.67 | 2024-2025 | Voquezna |
| Lucid Diagnostics INC. | $52.43 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $43.00 | 2024-2025 | Zenpep |
| Redhill Biopharma INC. | $36.63 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $33.65 | 2020-2021 | |
| Orphalan INC | $28.92 | 2025 | Cuvrior |
| Madrigal Pharmaceuticals | $26.29 | 2025 | Rezdiffra |
| Celgene Corporation | $24.37 | 2022 | |
| Allergan, INC. | $23.10 | 2019-2020 | |
| Genzyme Corporation | $22.83 | 2025 | |
| Intra-Sana Laboratories | $22.32 | 2021 | |
| La Jolla Pharmaceutical Company | $21.46 | 2023 | Xerava |
| Ferring Pharmaceuticals INC. | $18.62 | 2023 | Rebyota |
| Ardelyx, INC. | $16.81 | 2023 | Ibsrela |
| Shionogi INC | $13.10 | 2020 | |
| Medtronic, INC. | $12.76 | 2023 | Interstim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarek Ammar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.